Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Vasopressin (Vasostrict) peptide icon, one bubble per amino acidVasopressin (Vasostrict)9 residuesCYFQNCPRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Vasopressin (Vasostrict)

MetabolicFDA Approved
Up to 10 minutes half-life·Injection

Also known as: AVP, ADH, Antidiuretic Hormone

Vincent du Vigneaud won the 1955 Nobel Prize for synthesizing this nine-amino-acid hormone. Vasopressin (arginine vasopressin, AVP, antidiuretic hormone/ADH) is your body's primary blood pressure regulator during shock states. The VASST trial (778 patients)[1] and VANISH trial (409 patients)[2] established its role as an adjunctive vasopressor in septic shock. Vasostrict received FDA approval in 2014 for vasodilatory shock in adults. This is strictly a hospital ICU drug, administered by continuous intravenous infusion under direct physician supervision. No self-administration community exists, and none should.

What Is Vasopressin (Vasostrict)?

Two randomized controlled trials on 1,187 critically ill patients form the evidence base. That is a strong clinical foundation for a vasopressor, and vasopressin's data stands alongside the best-studied ICU drugs in use today.

Vasopressin (arginine vasopressin, AVP, antidiuretic hormone, ADH; CAS 113-79-1) is a cyclic nonapeptide with the sequence Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 and a disulfide bridge between positions 1 and 6. The hypothalamus synthesizes it as a preprohormone, and the posterior pituitary releases it when plasma osmolality rises or blood pressure drops.

The mechanism splits across three receptor pathways. V1a receptors on vascular smooth muscle drive vasoconstriction. V2 receptors on renal collecting duct cells promote water reabsorption through aquaporin-2 channels. V1b receptors in the anterior pituitary stimulate ACTH release. That triple action makes vasopressin effective even when catecholamine receptors are downregulated in prolonged shock.

The VASST trial (Russell et al., NEJM 2008, n=778) found no overall mortality difference versus norepinephrine, but showed a survival benefit in less severe septic shock (APACHE II 20 to 29). VANISH (Gordon et al., JAMA 2016, n=409) showed a vasopressin-first strategy reduced the need for renal replacement therapy. Surviving Sepsis Campaign 2021 guidelines recommend adding vasopressin at 0.03 U/min when norepinephrine exceeds 0.25 mcg/kg/min. Vasostrict (Par Pharmaceutical) holds the FDA approval, with generic competition from Eagle Pharmaceuticals and American Regent entering in 2022 to 2023.

How Vasopressin (Vasostrict) Works

V1a receptors sit on vascular smooth muscle, hepatocytes, and platelets. When vasopressin binds V1a, the Gq protein activates phospholipase C. This generates inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from the sarcoplasmic reticulum, causing smooth muscle contraction and vasoconstriction. That calcium-driven squeeze on blood vessels is the primary vasopressor effect in shock states.

Vasopressin also blocks nitric oxide-mediated vasodilation. In septic shock, pathological overproduction of NO drives refractory hypotension. Catecholamine receptors become downregulated after prolonged exposure to endogenous adrenaline and noradrenaline. Vasopressin bypasses that problem entirely; V1a receptors operate through a separate signaling cascade that remains responsive when adrenergic pathways fail.

V2 receptors on the basolateral membrane of renal collecting duct principal cells couple to Gs proteins. The downstream signal activates adenylyl cyclase, raising intracellular cAMP. Protein kinase A then phosphorylates aquaporin-2 water channels and moves them to the apical membrane. Water permeability increases dramatically. This is the antidiuretic mechanism that gave vasopressin its alternate name, ADH. V2 activation on vascular endothelium also releases von Willebrand factor multimers and coagulation Factor VIII from Weibel-Palade bodies.

V1b receptors in the anterior pituitary stimulate ACTH secretion through the Gq/PLC pathway. Vasopressin works with corticotropin-releasing hormone (CRH) to amplify the hypothalamic-pituitary-adrenal axis response during physiological stress.

Vasopressin (Vasostrict) Benefits

  • Vasopressin benefits center on hemodynamic rescue in critically ill patients unresponsive to standard catecholamine vasopressors.
  • FDA-approved vasopressor for vasodilatory shock refractory to fluid resuscitation and catecholamines (Vasostrict NDA 204485, approved 2014).
  • Catecholamine-sparing effect confirmed in both VASST and VANISH. Adding vasopressin at 0.03 U/min allows clinicians to reduce norepinephrine doses, lowering the risk of catecholamine-related arrhythmias.
  • VANISH (n=409)[2] showed a signal toward reduced need for renal replacement therapy in the vasopressin-first group compared to norepinephrine-first.
  • Effective when adrenergic pathways fail. V1a receptor vasoconstriction works through a completely separate mechanism from catecholamines, restoring vascular tone even in prolonged shock with receptor downregulation.
  • Releases von Willebrand factor and Factor VIII from vascular endothelium (V2-mediated), providing an additional hemostatic benefit in bleeding patients.
  • VASST subgroup analysis showed a survival benefit in less severe septic shock (APACHE II scores 20 to 29, n=778)[1].

Vasopressin (Vasostrict): Science vs Community Consensus

Science Only
Scientific Evidence
Strong
Based on 7 key studies·FDA-approved

FDA-approved (Vasostrict, 2014) vasopressor for vasodilatory shock.

Dosing studied: Septic shock: 0.01–0.07 U/min IV continuous infusion adjunct to catecholamines. Postcardiotomy shock: 0.03–0.1 U/min (FDA label max). Standard target: add vasopressin at 0.03 U/min when norepinephrine >0.25 mcg/kg/min.
Read the evidence (key study, limitations)

VASST (NEJM 2008, n=778) showed no overall mortality difference vs. norepinephrine but a survival benefit in less severe septic shock (APACHE II 20–29). VANISH (JAMA 2016, n=409) showed vasopressin-first strategy reduced kidney failure (fewer patients requiring CRRT) vs. norepinephrine-first, with no mortality benefit. SSC 2021 guidelines recommend vasopressin as a second-line vasopressor at 0.03 U/min when MAP target not met on norepinephrine alone.

Key Study

VASST (Russell et al., NEJM 2008, PMID 18305265, n=778); VANISH (Gordon et al., JAMA 2016, PMID 27483065, n=409)

Limitations

No overall mortality benefit in VASST or VANISH. Benefit restricted to less severe septic shock subgroup in VASST. VANISH primary endpoint (renal failure) showed trend but was underpowered for mortality. Optimal timing, dose, and patient selection remain debated. All evidence is from ICU RCTs: no outpatient or community data exists by definition.

Community Experience
Weak
3.5/5
Based on 0 consumer reports: hospital-only drug

No consumer or self-administration community exists.

Community dosing: Not applicable: hospital ICU-administered continuous infusion only
Read the reports (what users report 4, common issues 5)

Vasopressin is an ICU-only continuous IV infusion drug. "Community" context consists entirely of clinical professionals (ICU nurses, critical care physicians) in r/nursing, r/medicine, and r/criticalcare: discussing clinical protocols, not self-use. There is no self-administration market or compounding interest.

What users report (4)
  • Catecholamine-sparing effect: reduces norepinephrine requirements in septic shock
  • Signal toward reduced renal replacement therapy requirements (VANISH trial)
  • No catecholamine-associated tachycardia or arrhythmias
  • Effective even when catecholamine receptors are downregulated (prolonged shock)
Common issues (5)
  • Digital and peripheral ischemia risk with higher doses or prolonged infusion
  • Mesenteric ischemia risk: abdominal monitoring required during infusion
  • Extreme price increase post-NDA approval (pre-2014 ~$1/dose → ~$158/dose at peak 2022)
  • Mandatory taper: abrupt discontinuation causes rebound hypotension and transient DI in ~1.5% of patients
  • Must be diluted from 20 U/mL concentrate: medication errors reported without premixed formulations
Science-Only Evidence

No consumer community exists. Vasopressin is exclusively administered by ICU clinicians. Within the scientific community, VASST and VANISH are aligned on adjunctive use alongside catecholamines at 0.01–0.07 U/min; SSC 2021 guidelines codify this as a weak recommendation with moderate-quality evidence. No divergence between trials and current practice guidelines on core dosing.

Vasopressin (Vasostrict) Dosage Guide

FDA LabelVasostrict (vasopressin injection) FDA Prescribing Information (2021)Source (opens in a new tab)
LevelRateFrequency
Beginner0.01 IUContinuous IV infusion (units/minute)
Moderate0.03 IUContinuous IV infusion (units/minute)
Aggressive0.07 IUTop of the label's septic-shock range, 0.01 to 0.07 U/min (section 2.2). The label has limited data above it and expects more adverse reactions at higher doses. Sepsis guidelines usually hold vasopressin at 0.03 U/min and link higher doses to cardiac, digital and splanchnic ischemia (PMID 34599691). Rates above 0.04 U/min may lead to adverse events, likely from vasoconstriction (PMID 11555538).Continuous IV infusion (units/minute)
Note:

Vasopressin is not a self-administration peptide. Everything here applies to ICU clinicians managing the drug on a ventilated or monitored patient.

Standard ICU concentration is 0.1 U/mL. Dilute 25 units into 250 mL of 0.9% normal saline or D5W. At that concentration, 0.01 U/min equals 6 mL/hr, 0.03 U/min equals 18 mL/hr, and 0.07 U/min equals 42 mL/hr on the infusion pump.

Premixed bags are available at 0.2, 0.4, and 0.6 U/mL concentrations. Use them when possible. The 20 U/mL concentrate vials look similar to the diluted infusion bags, and medication errors from that confusion are documented.

Smart pump drug libraries reduce rate-programming errors. Never bolus vasopressin; it causes severe acute hypertension and myocardial ischemia. Start the taper once MAP holds at 65 mmHg for 8 hours without catecholamines. Reduce by 0.005 U/min every hour as tolerated (Vasostrict label, section 2.2), and monitor sodium and urine output for 24 to 48 hours after the infusion stops completely.

Cycling

Vasopressin is used acutely in critical care settings, not cycled. Continuous IV infusion is titrated to hemodynamic targets and tapered gradually when the patient stabilizes. Typical duration of use ranges from hours to several days. Abrupt discontinuation should be avoided due to the risk of rebound hypotension and transient diabetes insipidus.

Calculate your Vasopressin (Vasostrict) dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Vasopressin (Vasostrict) Protocols by Goal

beginnerFDA LabelHours to several days (median 2–4 days in VASST and VANISH). Not a long-term therapy.
Initiation
Wk N/A (acute ICU use: hours to days)
0.01 U/min · Continuous IV infusion: titrate up q10–15 min as needed · Intravenous (central venous line preferred)
Titration to target MAP
Wk N/A
0.01–0.07 U/min · Continuous infusion; titrate by 0.005 U/min increments every 10–15 min · Intravenous
Taper and Discontinuation
Wk N/A
Reduce by 0.005 U/min every hour as tolerated (Vasostrict label, section 2.2) · Gradual reduction: do NOT stop abruptly · Intravenous

Expected: Restoration of MAP ≥65 mmHg; reduction in norepinephrine requirements; potential reduction in renal replacement therapy need (VANISH signal)

Monitor: Continuous arterial line blood pressure monitoring mandatory. Hourly urine output. Daily serum sodium and electrolytes. Monitor for digital ischemia (finger/toe color and temperature). Abdominal assessment for mesenteric ischemia signs.

How to Use Vasopressin (Vasostrict)

  1. 1
    Confirm central venous access

    Peripheral IV is acceptable only for short durations (under 30 to 60 minutes) when central access is not available.

  2. 2
    Prepare the infusion

    Dilute 25 units of vasopressin concentrate (20 U/mL) into 250 mL of 0.9% normal saline or D5W for a final concentration of 0.1 U/mL. Alternatively, use a premixed bag (0.2, 0.4, or 0.6 U/mL).

  3. 3
    Step 3

    Set the infusion pump to 6 mL/hr (0.01 U/min at 0.1 U/mL concentration). Do not administer as a bolus under any circumstances.

  4. 4
    Step 4

    Titrate upward by 0.005 U/min (3 mL/hr increments at 0.1 U/mL) every 10 to 15 minutes until MAP reaches 65 mmHg or higher.

  5. 5
    Maximum rate for septic shock: 0.07 U/min (42 mL/hr)

    For postcardiotomy shock: 0.1 U/min (60 mL/hr). Rates above 0.04 U/min may lead to adverse events, likely from vasoconstriction (PMID 11555538 (opens in a new tab)); guidelines usually hold at 0.03 U/min (PMID 34599691 (opens in a new tab)).

  6. 6
    Step 6

    Monitor continuously: arterial blood pressure, hourly urine output, serum sodium every 12 to 24 hours, digital perfusion every 2 to 4 hours, and daily abdominal assessment.

  7. 7
    Step 7

    Taper once target blood pressure has held for 8 hours without catecholamines: decrease by 0.005 U/min every hour as tolerated (Vasostrict label, section 2.2). Never stop abruptly.

  8. 8
    Step 8

    Post-discontinuation: monitor sodium and urine output for 24 to 48 hours. Watch for transient diabetes insipidus (sudden polyuria and hypernatremia) in approximately 1.5% of patients.

Alternative Routes

Central venous line (CVC): continuous IV infusion

Standard dosing 0.01–0.07 U/min (septic shock) or 0.03–0.1 U/min (postcardiotomy)

Dedicated central line strongly preferred. Extravasation from peripheral IV causes local tissue necrosis. Premixed 0.2/0.4/0.6 U/mL bags designed for central administration.

Peripheral IV: continuous infusion

Same dosing; higher extravasation risk

Peripheral IV acceptable in emergencies when central access not immediately available. Limit to ≤30–60 min. Monitor site continuously. Switch to central line as soon as possible. Extravasation antidote: phentolamine 5–10 mg SC in 10 mL NS at site.

Intramuscular (IM) or Subcutaneous (SC)

Unpredictable absorption; not studied for vasodilatory shock

FDA label lists IM/SC for non-shock indications (e.g., diabetes insipidus) but not used in critical care shock management. Onset delayed and bioavailability variable: unsuitable for hemodynamic emergencies.

Vasopressin (Vasostrict) Stacking Protocols

Works With

Norepinephrine

Standard combination in septic shock. Vasopressin acts via V1a receptor (non-adrenergic) allowing norepinephrine dose reduction (catecholamine-sparing). VASST and VANISH both used this combination. SSC 2021 recommends adding vasopressin at 0.03 U/min when NE >0.25 mcg/kg/min.

Vasopressin 0.03 U/min + norepinephrine; titrate norepinephrine down as MAP allows

Hydrocortisone (corticosteroids)

VANISH trial included a 2×2 factorial arm for hydrocortisone. SSC 2021 recommends IV hydrocortisone 200 mg/day in patients with septic shock not responding to fluids and vasopressors. Often co-administered with vasopressin as standard septic shock management.

IV hydrocortisone 200 mg/day (50 mg q6h or continuous infusion) alongside vasopressin

Avoid

SSRIs, carbamazepine, chlorpropamide (SIADH-causing drugs)

Amplify antidiuretic (V2) effect of vasopressin, dramatically increasing risk of severe hyponatremia and fluid overload. May also potentiate pressor effect unpredictably.

Do not combine
Lithium, demeclocycline, foscarnet (DI-causing drugs)

Antagonize vasopressin V2 receptor activity, reducing antidiuretic effect and potentially blunting vasopressor response. May require higher vasopressin doses to achieve hemodynamic targets.

Indomethacin / NSAIDs

NSAIDs prolong and potentiate both vasopressin pressor and antidiuretic effects, increasing ischemia risk and risk of hyponatremia.

Estimated Cost

Brand Price
Vasostrict 20 U/mL concentrate: ~$1,944 retail (4×1 mL vials; Par Pharmaceutical/Endo International). Premixed bags (20 U/100 mL D5W): ~$341–$674/bag
Generic / Research
Vasopressin injection 20 U/mL: ~$314 retail (2×1 mL vials; Eagle Pharmaceuticals, American Regent). ~50% lower than brand since generic entry 2022–2023
Compounded
Pre-2014: ~$1/dose as unapproved compounded drug. Compounding effectively eliminated after Par Pharmaceutical obtained FDA NDA (2014) and used market exclusivity. 503B outsourcing facilities may supply limited quantities during shortage periods.

Pricing updated 2026-04-09

Vasopressin (Vasostrict) Side Effects

Peripheral ischemia is the most serious concern. Vasopressin's V1a-mediated vasoconstriction can cause digital ischemia, presenting as finger or toe blanching, cyanosis, and in severe cases, skin necrosis or gangrene. Rates above 0.04 U/min may lead to adverse events, likely from vasoconstriction (PMID 11555538 (opens in a new tab)). Sepsis guidelines hold the dose at 0.03 U/min and trials went up to 0.06 (PMID 34599691 (opens in a new tab)); the label's septic-shock ceiling is 0.07 U/min, with limited data above it (section 2.2). Mesenteric ischemia is the other major danger, presenting as abdominal pain, ileus, or bowel necrosis. Both complications require immediate dose reduction or discontinuation.

Cardiac effects include decreased cardiac output, bradycardia, and tachyarrhythmias. Patients with coronary artery disease face particular risk of myocardial ischemia. The FDA label carries explicit warnings about ischemic complications across all vascular territories.

Hyponatremia results from excessive water retention mediated by V2 receptor activation. Serum sodium should be checked every 12 to 24 hours during infusion. If sodium drops below 130 mEq/L, free water restriction and dose reduction are standard interventions.

Transient diabetes insipidus develops in approximately 1.5% of patients after abrupt discontinuation. Prolonged infusion causes V2 receptor downregulation in the kidneys. Stopping the drug suddenly leaves those downregulated receptors unable to respond to endogenous ADH, producing sudden polyuria and rising sodium levels. This is precisely why vasopressin must be tapered, never stopped cold. Rebound hypotension accompanies the V2 problem because vascular tone takes time to compensate without exogenous support.

Other reported effects include nausea, vomiting, abdominal cramping, headache, vertigo, and bronchospasm. Extravasation at the IV site causes local tissue necrosis due to the extreme vasoconstrictive potency; treat with subcutaneous phentolamine 5 to 10 mg in 10 mL normal saline at the site.

Contraindications: known hypersensitivity to 8-L-arginine vasopressin, coronary artery disease at risk for myocardial ischemia, peripheral vascular disease at risk for limb ischemia, and chronic nephritis with raised blood nitrogen. Pregnancy is FDA Category C; vasopressin may produce tonic uterine contractions threatening pregnancy continuation. It is excreted in breast milk.

When to stop: progressive digital ischemia despite dose reduction, any suspicion of mesenteric ischemia, myocardial ischemia (troponin rise, ECG changes), or refractory hyponatremia below 125 mEq/L.

Common Issues & Solutions

Rebound hypotension on discontinuation: always taper by 0.005 U/min per hour; never stop abruptly; monitor MAP for 30–60 min after each rate reduction

Digital ischemia (finger/toe blanching, cyanosis): reduce infusion rate; consider stopping if irreversible ischemia suspected; rates above 0.04 U/min may lead to adverse events, likely from vasoconstriction (PMID 11555538 (opens in a new tab))

Hyponatremia during infusion: V2 receptor stimulation causes excessive water retention; restrict free water, check sodium q12–24h, reduce dose if Na+ <130 mEq/L

Transient diabetes insipidus post-discontinuation (~1.5% incidence): sudden polyuria + rising sodium after stopping; monitor urine output and Na+ for 24–48h post-taper; treat with desmopressin if symptomatic

Peripheral extravasation causing tissue necrosis: use central venous line for infusions >30–60 min; if peripheral extravasation occurs, treat with subcutaneous phentolamine (5–10 mg in 10 mL NS)

Ask AI about this page

Ask AI for a second opinion on Vasopressin (Vasostrict) dosing and side effects

Contraindications

  • Known hypersensitivity to 8-L-arginine vasopressin or any formulation component
  • Patients with significant coronary artery disease at risk for myocardial ischemia
  • Patients with peripheral vascular disease at risk for digital or limb ischemia
  • Chronic nephritis with elevated blood nitrogen levels (relative contraindication)
  • Pregnancy: FDA Category C; may produce tonic uterine contractions that could threaten pregnancy continuation
  • Breastfeeding: vasopressin is excreted in breast milk; monitor nursing infants for water retention

Drug Interactions

  • Catecholamines (norepinephrine, epinephrine): additive vasopressor effect; monitor for excessive vasoconstriction
  • Indomethacin and other NSAIDs: may prolong and potentiate vasopressin pressor and antidiuretic effects
  • Ganglionic blocking agents: may increase sensitivity to vasopressin pressor effects
  • Drugs causing SIADH (SSRIs, carbamazepine, chlorpropamide): may amplify antidiuretic effect and worsen hyponatremia
  • Drugs causing diabetes insipidus (lithium, demeclocycline, foscarnet): may decrease vasopressin pressor response
  • Antagonize vasopressin V2 receptor activity, reducing antidiuretic effect and potentially blunting vasopressor response. May require higher vasopressin doses to achieve hemodynamic targets.

Product Quality

Recommended Monitoring

TestWhenTarget
Arterial blood pressure (MAP)Continuous during infusionMAP ≥65 mmHg (or per institutional protocol)
Urine outputHourly during infusion≥0.5 mL/kg/hr
Serum sodium (Na+)q12–24h during infusion; daily for 24–48h post-taper135–145 mEq/L
Serum electrolytes panelDaily during infusionNot listed
Digital/extremity perfusion assessmentq2–4h during infusion, especially at doses >0.04 U/minNot listed
Abdominal assessment (clinical)Daily and PRN during infusionNot listed
Arterial blood pressure (MAP)

Primary therapeutic target; vasopressin titrated to MAP ≥65 mmHg

Urine output

Antidiuretic V2 effect reduces urine output; oliguria may reflect ischemia vs. therapeutic effect

Serum sodium (Na+)

Hyponatremia risk from V2-mediated water retention during infusion; hypernatremia risk (transient DI) post-discontinuation

Serum electrolytes panel

Full electrolyte management in critically ill patients on vasopressors

Digital/extremity perfusion assessment

V1a-mediated vasoconstriction can cause digital ischemia, skin necrosis, and limb-threatening ischemia at higher doses

Abdominal assessment (clinical)

Mesenteric ischemia risk: abdominal pain, distension, or ileus may indicate bowel ischemia requiring dose reduction or discontinuation

Vasopressin (Vasostrict) Before and After

0-5 minutes

Rapid onset of vasopressor effect with measurable increase in mean arterial pressure

5-30 minutes

Hemodynamic stabilization with dose titration; reduction in catecholamine requirements

1-6 hours

Sustained vasopressor effect at steady-state infusion; antidiuretic effect with reduced urine output

6-72 hours

Continued hemodynamic support; monitor for ischemic complications and hyponatremia

Post-discontinuation

Effects resolve within minutes of stopping infusion; monitor for rebound hypotension and transient diabetes insipidus

What to Expect

Minutes 0 to 5: V1a receptor vasoconstriction begins almost immediately. Blood pressure rises on the arterial line monitor within 1 to 5 minutes of starting the infusion at 0.01 U/min. Some patients develop bradycardia; skin blanching at the infusion site is common.

Minutes 5 to 30: The ICU team titrates the rate upward toward MAP 65 mmHg. Norepinephrine dose reduction typically starts during this window. The antidiuretic V2 effect kicks in, and urine output drops. Nausea and abdominal cramping can appear.

Hours 1 to 6: Steady-state vasopressor effect establishes at the target infusion rate. Catecholamine requirements decrease measurably. Antidiuretic activity stabilizes. Nursing staff should begin watching for early signs of digital or peripheral ischemia and checking serum sodium.

Hours 6 to 96: The median vasopressin infusion in VASST lasted 3 days. During this window, monitoring shifts toward ischemic complications (digital ischemia, mesenteric ischemia presenting as abdominal symptoms) and electrolyte disturbances (hyponatremia from V2-mediated water retention).

Post-discontinuation (taper phase): The 10 to 20 minute half-life means pharmacological effects clear within minutes of stopping the pump. The risks shift to rebound hypotension during the taper and transient diabetes insipidus from V2 receptor downregulation in roughly 1.5% of patients. Polyuria and rising sodium levels can persist for 1 to 5 days. Monitor urine output and sodium for at least 24 to 48 hours after the infusion stops.

Detailed Timeline: Science vs Community

0–5 minutes
Science

Rapid V1a receptor-mediated vasoconstriction; measurable MAP increase within 1–5 minutes of starting infusion at 0.01 U/min

Community

N/A: ICU-administered; nursing staff observe hemodynamic response on monitors

5–30 minutes
Science

Dose titration to MAP target (≥65 mmHg); norepinephrine dose reduction begins; antidiuretic effect reduces urine output

Community

N/A

1–6 hours
Science

Sustained vasopressor effect at steady-state infusion rate; catecholamine requirements decrease; antidiuretic V2 effect stabilizes

Community

N/A

6–96 hours
Science

Continued hemodynamic support; VASST median vasopressin infusion was 3 days; monitor for ischemic complications and electrolyte disturbances

Community

N/A

Post-discontinuation (taper phase)
Science

Effects resolve within minutes of stopping infusion (t½ 10–20 min); risk of rebound hypotension during taper; V2 receptor downregulation may cause transient DI in ~1.5% of patients lasting 1–5 days

Community

N/A

Pharmacokinetics

Half-Life
10min
Bioavailability
IV: 100%; IM/SC: variable, not well characterized
Tmax
Immediate (IV continuous infusion); IM: 15-30 minutes
Data Confidence
high

Source: Vasostrict label, section 12.3: apparent half-life of 10 minutes or less at shock infusion rates (0.01 to 0.1 units/minute). Baumann and Dingman 1976 (PMID 1262458): mean plasma half-life 24.1 minutes in 10 healthy adults at physiological concentrations.

Pharmacokinetics: Active Dose Over Time

t½ = Up to 10 minutes (shock infusion, Vasostrict label); 24 minutes in healthy adults (Baumann 1976)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
9
Structure
Cyclic
Sequence
CYFQNCPRG
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider Vasopressin (Vasostrict)

  • ICU patients with vasodilatory or septic shock refractory to fluids and catecholamines
  • Patients with central diabetes insipidus (ADH deficiency)
  • Patients with acute variceal or GI hemorrhage requiring splanchnic vasoconstriction
  • Postcardiotomy shock patients requiring catecholamine-sparing vasopressor support
  • Cardiac arrest patients (ACLS protocol: alternative to epinephrine)

Related Peptides

What Changed for Vasopressin (Vasostrict)

  1. Dosing

    Corrected Oct 20, 2026: vasopressin's aggressive tier is 0.07 units/min, the top of the septic-shock range, per the Vasostrict label, section 2.2.

    Before: Aggressive tier 0.04 IU, Continuous IV infusion (units/minute), no caveat After: Aggressive tier 0.07 IU, Continuous IV infusion (units/minute), with a caveat: top of the label septic-shock range, limited data above it

    What this does not mean: Not a target rate. The label never states the old 0.04. It starts septic shock at 0.01 and post-cardiotomy shock at 0.03 units/min, has limited data above 0.07 and 0.1, and expects more adverse reactions at higher doses.

    Source: Vasostrict (vasopressin injection) prescribing information, section 2.2 (openFDA label record, SPL version 49, effective Apr 21, 2026) (opens in a new tab) · Saved copy

  2. Safety

    Corrected Oct 20, 2026: vasopressin's septic-shock ceiling is 0.07 units/min, with limited data above it, per the Vasostrict label, section 2.2.

    Before: Infusion rates above 0.04 U/min carry significantly raised risk. After: Rates above 0.04 U/min may lead to adverse events (PMID 11555538); guidelines hold 0.03 U/min; the label's septic-shock ceiling is 0.07 U/min, with limited data above it (section 2.2)

    What this does not mean: The old line said rates above 0.04 carry significantly raised risk, with no source. It now cites Holmes 2001 (PMID 11555538): above 0.04 may lead to adverse events, likely from vasoconstriction.

    Source: Vasostrict (vasopressin injection) prescribing information, section 2.2 (openFDA label record, SPL version 49, effective Apr 21, 2026) (opens in a new tab) · Saved copy

  3. Dosing

    Corrected Oct 18, 2026: vasopressin's tiers are infusion rates in units per minute, not daily doses, per the Vasostrict label, section 2.2.

    Before: 0.01, 0.03 and 0.04 IU, each labelled Daily After: 0.01, 0.03 and 0.04 IU, each labelled Continuous IV infusion (units/minute)

    What this does not mean: The numbers did not change. The label starts septic shock at 0.01 and post-cardiotomy shock at 0.03 units per minute, titrated by a clinician on a pump.

    Source: Vasostrict (vasopressin injection) prescribing information, section 2.2 (openFDA label record, SPL version 49, effective Apr 21, 2026) (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Apr 8, 20268 Citations

References

  1. [1]Vasopressin versus norepinephrine infusion in patients with septic shock (VASST Trial) (opens in a new tab)PubMed (opens in a new tab)Clinical Trial
  2. [2]Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial (opens in a new tab)PubMed (opens in a new tab)Clinical Trial
  3. [3]FDA NDA 204485

Related Tools

Storage & Stability

Before Reconstitution
Not applicable: supplied as ready-to-use liquid injection
After Reconstitution
Diluted solutions stable 18 hours at room temperature or 24 hours refrigerated
Temperature
2-8°C (refrigerated); may store at 20-25°C room temperature for up to 12 months

Frequently Asked Questions

Vasopressin works through a completely different receptor pathway (V1a vasoconstriction vs adrenergic). It can restore vascular tone even when catecholamine receptors are downregulated in prolonged shock. Adding vasopressin at 0.03 U/min allows you to reduce norepinephrine dose, potentially lowering catecholamine-related arrhythmias and tachycardia without losing blood pressure control.

It's been in ACLS algorithms as an alternative to epinephrine for pulseless arrest. Evidence is mixed: comparable outcomes to epinephrine in some studies but no clear superiority. The 2020 AHA guidelines de-emphasized vasopressin as a standalone agent and removed it as a first-line alternative, though some institutional protocols still include it.

Prolonged infusion causes V2 receptor downregulation in the kidneys. Stopping suddenly allows rebound vasodilation (hypotension) before the vascular system compensates, and the downregulated V2 receptors temporarily can't respond to your body's own ADH, causing transient diabetes insipidus (excessive urination + high sodium) in about 1.5% of patients.

Before 2014, vasopressin was an unapproved compounded drug costing roughly $1/dose. Par Pharmaceutical got an FDA NDA for Vasostrict in 2014 and used market exclusivity to eliminate compounded competition, jacking hospital costs to about $158/dose by 2022. It drew congressional attention as an example of FDA "evergreening." Generic competition entering 2022-2023 has brought prices down by around 50%.

The FDA label recommends a dedicated central venous line because peripheral extravasation causes local tissue necrosis due to extreme vasoconstrictive potency. However, peripheral IV is acceptable for short durations when central access isn't available: consistent with emergency medicine practice. Central line is strongly preferred for infusions lasting more than 30-60 minutes.